Owen Mumford is a family owned company that has over fifty years' experience as a world leader in the design, development and manufacture of medical devices. Healthcare professionals and consumers worldwide use these devices.
At its Cotswold division in Chipping Norton, Owen Mumford moulds, assembles and packs automatic injection devices, which patients use to administer pharmaceutical product from pre-filled syringes or cartridges, for the treatment of chronic or degenerative conditions, such as diabetes, multiple sclerosis and rheumatoid arthritis.
A growth in the number of medical conditions which are self managed by the patient, by self-injecting medication using bespoke autoinjector and pen technology, has led to an increased demand for the type of medical devices produced by Owen Mumford. Owen Mumford manufactures a range of its own branded products for hospitals, clinics and pharmacies, as well as developing products on behalf of pharmaceutical and diagnostic companies.
The new facility will more than double the existing space available for the manufacture of drug delivery devices and reusable lancing devices. The site will also feature a class 9 clean room environment and cold chain management facility, for the manufacture of drug device combination products. A significant part of the new space will be devoted to fully automated assembly equipment, for high speed, high volume manufacture of new devices.
At the opening, Adam Mumford, Managing Director of Owen Mumford, and Martyn Young, General Manager of Owen Mumford's Cotswold Division, will be on hand to welcome guests and outline the company's commitment to its employees and the local community in Chipping Norton.
Commenting on the company's expansion, Adam Mumford, Managing Director of Owen Mumford, says: "As a successful and growing business, this expanded site will enable us to produce more new products and greater volumes, to meet the increased demand from patients, healthcare professionals and pharmaceutical and diagnostic partners. This state of the art facility further cements our position as a world leader in the production of autoinjectors and allows for further expansion in the future."
Please confirm your attendance, in advance, by contacting Tracey Halstead on 01663 734 789 or Carol Laing on 01663 735 160.